Fibronostics will be guests at the EASL congress in Vienna, Austria to present ‘NAFLD: Diagnostics and non-invasive assessment’.
Join Dr. Mona Munteanu, our Chief Scientific Officer, on 24 June between 09:00 – 17:00 where she will discuss ‘LIVERSTAT, first-line screening tool in at-risk MAFLD patients outperforms the standard-of-care (SOC) FIB-4’
We can’t wait to network with others in the industry, learn more about advancements in liver health, and take home knowledge we can apply to our current processes.
Find out more: https://easl.eu/event/easl-congress-2023/
